ClinicalTrials.gg
RecruitingNCT07252414Updated Oct 30, 2026

GenSci143 in Participants With Advanced Solid Tumors

A Phase 1 interventional study of GenSci143 for injection in Advanced Solid Tumors, sponsored by Changchun GeneScience Pharmaceutical Co., Ltd.. Recruiting at 13 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.
Updated Oct 30, 2026First site in United StatesSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
180
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of GenSci143 in Participants with Advanced Solid Tumors

Read the detailed description

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of GenSci143 in Participants with Advanced Solid Tumors

02

Conditions studied

  • Advanced Solid Tumors
03

In context

Lead sponsor

Changchun GeneScience Pharmaceutical Co., Ltd. is the lead sponsor of 112 studies on the registry; 47 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Oct 30, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntarily sign the ICF.
  • Male or female participants ≥18 years old at the time of signing the ICF.
  • Meet the requirements of tumor types as outlined below:

    1. Dose escalation: Participants with or cytologically documented recurrent or advanced solid tumors, and who have progressed after standard therapy, are intolerant to standard therapy, or have no standard therapy available.
    2. Dose expansion:

Cohort 1: Participants with histologically or cytologically documented mCRPC,who had received at least one prior novel hormonal therapy (including but not limited to abiraterone, enzalutamide, darolutamide, apalutamide) and progressed on standard chemotherapy regimens, are intolerant to chemotherapy, or decline chemotherapy.

Cohort 2: Participants with histologically or cytologically documented other advanced solid tumors, and who have progressed after standard therapy, are intolerant to standard treatment, or have no standard therapy available.

  • of ≥ 12 weeks.
  • PS 0-1
  • Have at least 1 evaluable tumor lesion according to v1.1. Participants with mCRPC who have bone only disease may be eligible on a case-by-case basis after discussion between the investigator and Sponsor
  • Able to provide either archival or fresh formalin-fixed paraffin-embedded (FFPE) tumor samples.
  • Adequate organ function at the time of screening, as outlined below:

    1. Hematology: (ANC) ≥ 1.5×109/L (1500/µL); count (PLT)≥100×109/L (100,000/µL); (HGB) ≥ 90 g/L (9 g/dL) (have not received granulocyte colony-stimulating factor (G-CSF) within 7 days before the first dose of GenSci143, and have not received granulocyte-macrophage colony-stimulating factor (GM-CSF), blood transfusion, erythropoietin (EPO), platelet transfusion, thrombopoietin (TPO), or interleukin-11 (IL-11) within 14 days before the first dose of GenSci143).
    2. Liver function: Serum total (TBIL) ≤ 1.5 (ULN), and serum TBIL≤ 3×ULN in the presence of liver metastasis or documented Gilbert syndrome. (ALT) and aspartate aminotransferase (AST) ≤ 3×ULN if no liver metastasis; ALT and AST≤ 5×ULN in the presence of liver metastasis.
    3. Renal function: (CLcr) ≥ 50 mL/min as calculated using the Cockcroft-Gault formula.
    4. Coagulation function: (PT), activated partial thromboplastin time (APTT), and international normalized ratio (INR) ≤ 1.5×ULN (or within target range if on anticoagulation therapy).
  • Toxicities (other than alopecia) from previous anticancer therapy must have resolved to v5.0 Grade ≤1.
  • Women of (WOCBP) must have a serum pregnancy test negative within 7 days before the first dose of GenSci143. WOCBP must agree to use highly effective methods and must not donate or retrieve ova for personal use from the time of until 6 months after the last dose of GenSci143. Male participants must agree to use highly effective contraceptive methods and must not freeze or donate sperm from the time of informed consent until 6 months after the last dose of GenSci143.

Exclusion criteria

Exclusion Criteria:

  • Participants with known spinal cord compression or active central nervous system (CNS) , unless they are asymptomatic or have achieved post-treatment stability for >4 weeks and discontinued for >2 weeks before the first dose of GenSci143.
  • History of other known within the past 3 years.
  • Unstable thrombotic events requiring therapeutic intervention within 6 months before the first dose of GenSci143.
  • Uncontrolled or cardiovascular disease.
  • Uncontrolled pleural fluid, pericardial effusion, or ascites requiring drainage, and/or diuretics within 2 weeks before the first dose of GenSci143.
  • History of (non-infectious) interstitial lung disease (ILD)/pneumonitis that requires steroids, current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at Screening. Any , connective tissue, or inflammatory disorders with suspected pulmonary involvement.
  • Pregnant, breastfeeding, or planning to become pregnant.
  • Known active virus (HBV) or virus (HCV) infection.
  • Known (HIV) infection
  • Uncontrolled infection that requires systemic therapy with IV antibiotics, antivirals, or antifungals within 1 week before the first dose of GenSci143.
  • Major surgery (excluding diagnostic surgery), radiotherapy, and immunotherapy within 4 weeks before the first dose of medication; Chemotherapy or antibody therapy within 3 weeks; Endocrine therapy and small molecule-targeted therapy within 2 weeks or 5 half-lives(whichever is shorter). Androgen-deprivation therapy with gonadotropin-releasing hormone (GnRH) analogues (either GnRH agonists or GnRH antagonists) was allowed for men with prostate cancer.
  • Received any within 4 weeks before the first dose of GenSci143 or intend to receive a live vaccine during the study.
  • History of hematopoietic stem cell transplantation (HSCT) or solid organ transplantation.
  • Prior treatment with an ADC that consists of a topoisomerase inhibitor.
  • History of severe reactions to GenSci143 and/or in the drug product, or other monoclonal antibodies.
  • Any illness (uncontrolled hypertension, serious diabetes mellitus, thyroid disorders, and psychiatric disorders, etc.) or other conditions that are not eligible for inclusion based on the investigator's judgment.
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    GenSci143 for injection

    Drug: GenSci143 for injection

Interventions

  • DrugGenSci143 for injection

    GenSci143 for injection, administered Q3W, with a dosage ranging from 0.5mg/kg to 4.5mg/kg.

06

What researchers measure

Primary outcomes

  1. Part 1 and Part2:Incidence of adverse events Percentage of patients with adverse events by system organ class and preferred term.

    Time frame: From time of informed consent to 30days post last dose of GenSci143

  2. Part1:Dose limiting toxicities(DLTs),DLTs are assessed during the DLT observation period and defined as any toxicity in DLT definition in the Clinical Study Protocal

    Time frame: Form time of first dose of GenSci143 to end of DLT observation period(approximately 21 days)

  3. Part1: Maximum tolerated dose (MTD) and recommended dose for expansion (RDE) To determine the maximum tolerated dose (MTD) (if applicable) and recommended dose for expansion (RDE) of GenSci143.

    Time frame: Form time of first dose of GenSci143 up to 12 months.

  4. Part1: Part2: Composite response rate To evaluate the efficacy of GenSci143 as using RECIST v1.1 and/or PSA50 response (PCWG3) with PC

    Time frame: Approximately 12 months.

  5. Part1: Part2: Objective response rate(ORR) To evaluate the efficacy of GenSci143 as measured by ORR using RECIST v1.1 for participants with non-PC

    Time frame: Approximately 12 months.

Secondary outcomes

  1. AUC of GenSci143 Calculate area under the curve of GenSci143.

    Time frame: Approximately 12 months.

  2. AUC of total antibody Calculate area under the curve of total antibody.

    Time frame: Approximately 12 months

Other outcomes

  1. AUC of unconjugated payload. Calculate area under the curve of unconjugated payload

    Time frame: Approximately 12 months

  2. Cmax of GenSci143 Calculate maximum concentration of GenSci143.

    Time frame: Approximately 12 months

  3. Cmax of total antibody Calculate maximum concentration of total antibody

    Time frame: Approximately 12 months

  4. Cmax of unconjugated payload Calculate maximum concentration of unconjugated payload

    Time frame: Approximately 12 months

  5. Tmax of GenSci143 Calculate time of maximum concentration of GenSci143

    Time frame: Approximately 12 months

  6. Tmax of total antibody Calculate time of maximum concentration of total antibody

    Time frame: Approximately 12 months

  7. Tmax of unconjugated payload Calculate time of maximum concentration of unconjugated payload

    Time frame: Approximately 12 months

  8. CL of GenSci143 Calculate Cleanrance of GenSci143

    Time frame: Approximately 12 months

  9. CL of total antibody Calculate Cleanrance of total antibody

    Time frame: Approximately 12 months

  10. CL of unconjugated payload Calculate Cleanrance of unconjugated payload

    Time frame: Approximately 12 months

  11. V of GenSci143 Calculate apparent volume of distribution of GenSci143

    Time frame: Approximately 12 months

  12. V of total antibody Calculate apparent volume of distribution of total antibody

    Time frame: Approximately 12 months

  13. V of unconjugated payload Calculate apparent volume of distribution of unconjugated payload

    Time frame: Approximately 12 months

  14. t1/2 of GenSci143 Calculate time of half-life of GenSci143

    Time frame: Approximately 12 months

  15. t1/2 of total antibody Calculate time of half-life of total antibody

    Time frame: Approximately 12 months

  16. t1/2 of unconjugated payload Calculate time of half-life of unconjugated payload

    Time frame: Approximately 12 months

  17. ADC of GenSci143 Incidence and titer of anti-drug antibody(ADA)

    Time frame: Approximately 12 months

  18. NAb of GenSci143 Incidence and titer of anti-drug neutralizing(NAb)

    Time frame: Approximately 12 months

  19. Prostate-specific antigen (PSA)50 response rate To evaluate the preliminary anti-tumor activity of GenSci143 by PSA50 as PCWG3 criteria and RECIST v1.1 with PC

    Time frame: Approximately 12 months

  20. PSA90 response rate To evaluate the preliminary anti-tumor activity of GenSci143 by PSA90 as PCWG3 criteria and RECIST v1.1 with PC.

    Time frame: Approximately 12 months

  21. Best PSA response To evaluate the preliminary anti-tumor activity of GenSci143 by best PSA response as PCWG3 criteria and RECIST v1.1 with PC.

    Time frame: Approximately 12 months

  22. PSA progression-free survival (PSA-PFS) To evaluate the preliminary anti-tumor activity of GenSci143 by PSA-PFS as PCWG3 criteria and RECIST v1.1 with PC.

    Time frame: Approximately 12 months

  23. radiological PFS (rPFS) To evaluate the preliminary anti-tumor activity of GenSci143 by rPFS as PCWG3 criteria and RECIST v1.1 with PC.

    Time frame: Approximately 12 months

  24. failure-free survival (FFS) To evaluate the preliminary anti-tumor activity of GenSci143 by FFS as PCWG3 criteria and RECIST v1.1 with PC.

    Time frame: Approximately 12 months

  25. overall survival (OS) To evaluate the preliminary anti-tumor activity of GenSci143 by OS as PCWG3 criteria and RECIST v1.1 with PC.

    Time frame: Approximately 12 months

  26. objective response rate (ORR) To evaluate the preliminary anti-tumor activity of GenSci143 by ORR as PCWG3 criteria and RECIST v1.1 with PC.

    Time frame: Approximately 12 months

  27. disease control rate (DCR) To evaluate the preliminary anti-tumor activity of GenSci143 by DCR as PCWG3 criteria and RECIST v1.1 with PC.

    Time frame: Approximately 12 months

  28. duration of response (DoR) To evaluate the preliminary anti-tumor activity of GenSci143 by DoR as PCWG3 criteria and RECIST v1.1 with PC.

    Time frame: Approximately 12 months

  29. time to response (TTR) To evaluate the preliminary anti-tumor activity of GenSci143 by TTR as PCWG3 criteria and RECIST v1.1 with PC.

    Time frame: Approximately 12 months

  30. depth of response (DpR) To evaluate the preliminary anti-tumor activity of GenSci143 by DpR as PCWG3 criteria and RECIST v1.1 with PC.

    Time frame: Approximately 12 months

  31. overall survival (OS) To evaluate the preliminary anti-tumor activity of GenSci143 by OS as RECIST v1.1 with non-PC.

    Time frame: Approximately 12 months

  32. objective response rate (ORR) To evaluate the preliminary anti-tumor activity of GenSci143 by ORR as RECIST v1.1 with non-PC.

    Time frame: Approximately 12 months

  33. disease control rate (DCR) To evaluate the preliminary anti-tumor activity of GenSci143 by DCR as RECIST v1.1 with non-PC.

    Time frame: Approximately 12 months

  34. duration of response (DoR) To evaluate the preliminary anti-tumor activity of GenSci143 by DoR as RECIST v1.1 with non-PC.

    Time frame: Approximately 12 months

  35. time to response (TTR) To evaluate the preliminary anti-tumor activity of GenSci143 by TTR as RECIST v1.1 with non-PC.

    Time frame: Approximately 12 months

  36. depth of response (DpR) To evaluate the preliminary anti-tumor activity of GenSci143 by DpR as RECIST v1.1 with non-PC.

    Time frame: Approximately 12 months

07

Study locations

9 of 13 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for Oct 2028, 34 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2025
First posted
Nov 26, 2025
StartActual
Dec 20, 2025
Primary completionEst.
Oct 30, 2028
CompletionEst.
Jun 30, 2029
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites added — first site in United States. 5 sites changed recruiting status (5 now recruiting)
Show 5 sites
  • Hunan Cancer Hospital · Changsha, ChinaNot yet recruiting→Recruiting
  • Shandong Cancer Hospital · Jinan, ChinaNot yet recruiting→Recruiting
  • Zhongshan Hospital Affiliated to Fudan University · Shanghai, ChinaNot yet recruiting→Recruiting
  • The First Hospital of Shanxi Medical University · Taiyuan, ChinaNot yet recruiting→Recruiting
  • The First Affiliated Hospital of Zhejiang University School of Medicine · Hangzhou, ChinaNot yet recruiting→Recruiting
Show 4 added (4 United States)
  • START - Los Angeles - EDOS · Los Angeles, United States
  • Carolina Biooncology Institute · Huntersville, United States
  • SCRI OU Health Stephenson Cancer Center · Oklahoma City, United States
  • Medical Oncology Associates - Spokane · Spokane, United States
Oct 30, 2026
Eligibility
1 exclusion criterion edited
What changed in the criteria
Exclusion criteria
  • EditedPrior treatment with a topoisomerase inhibitor or an ADC that consists of a topoisomerase inhibitor.
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    4 sites added — first site in United States. 5 sites changed recruiting status (5 now recruiting)
    Show 5 sites
    • Hunan Cancer Hospital · Changsha, ChinaNot yet recruiting→Recruiting
    • Shandong Cancer Hospital · Jinan, ChinaNot yet recruiting→Recruiting
    • Zhongshan Hospital Affiliated to Fudan University · Shanghai, ChinaNot yet recruiting→Recruiting
    • The First Hospital of Shanxi Medical University · Taiyuan, ChinaNot yet recruiting→Recruiting
    • The First Affiliated Hospital of Zhejiang University School of Medicine · Hangzhou, ChinaNot yet recruiting→Recruiting
    Show 4 added (4 United States)
    • START - Los Angeles - EDOS · Los Angeles, United States
    • Carolina Biooncology Institute · Huntersville, United States
    • SCRI OU Health Stephenson Cancer Center · Oklahoma City, United States
    • Medical Oncology Associates - Spokane · Spokane, United States
    Eligibility 1 exclusion criterion edited
    What changed in the criteria
    Exclusion criteria
    • EditedPrior treatment with a topoisomerase inhibitor or an ADC that consists of a topoisomerase inhibitor.
    + 1 other change: oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07252414
Responsible party
Sponsor
First posted
Nov 26, 2025
Start date
Dec 20, 2025
Primary completion
Oct 30, 2028 (estimated)
Completion
Jun 30, 2029 (estimated)
Last update
Oct 30, 2026

Study contacts

Dingwei Ye
Contact
dwyeli@163.com
+86 13701663571

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion